MedTrace Logo

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

NCT04115436 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-10-17

No results posted yet for this study

Summary

Life-long therapy with oral anticoagulants (OAC) is strongly recommended in AF patients receiving left atrial appendage isolation (LAAI) to prevent thromboembolic (TE) events. However, some patients are observed to remain stroke-free while off OACs for years whereas others experience TE events if OAC is discontinued even for a short period of time. Therefore, we aim to evaluate the association of genetic variants (single nucleotide polymorphisms - SNPs) with off-anticoagulation stroke-risk in AF patients.

Conditions

  • Thromboembolic Events

Sponsors & Collaborators

  • Texas Cardiac Arrhythmia Research Foundation

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-10-01
Completion
2020-10-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04115436 on ClinicalTrials.gov